Your browser doesn't support javascript.
loading
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu, Sattva S; Jacobson, Caron A; Ghobadi, Armin; Miklos, David B; Lekakis, Lazaros J; Oluwole, Olalekan O; Lin, Yi; Braunschweig, Ira; Hill, Brian T; Timmerman, John M; Deol, Abhinav; Reagan, Patrick M; Stiff, Patrick; Flinn, Ian W; Farooq, Umar; Goy, Andre H; McSweeney, Peter A; Munoz, Javier; Siddiqi, Tanya; Chavez, Julio C; Herrera, Alex F; Bartlett, Nancy L; Bot, Adrian A; Shen, Rhine R; Dong, Jinghui; Singh, Kanwarjit; Miao, Harry; Kim, Jenny J; Zheng, Yan; Locke, Frederick L.
Affiliation
  • Neelapu SS; Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Jacobson CA; Dana-Farber Cancer Institute, Boston, MA.
  • Ghobadi A; Division of Medical Oncology, Washington University School of Medicine, St Louis, MO.
  • Miklos DB; Department of Medicine-Med/Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA.
  • Lekakis LJ; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL.
  • Oluwole OO; Vanderbilt-Ingram Cancer Center, Nashville, TN.
  • Lin Y; Department of Hematology, Mayo Clinic, Rochester, MN.
  • Braunschweig I; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
  • Hill BT; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.
  • Timmerman JM; Division of Hematology and Oncology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA.
  • Deol A; Karmanos Cancer Center, Wayne State University, Detroit, MI.
  • Reagan PM; Department of Medicine, University of Rochester School of Medicine, Rochester, NY.
  • Stiff P; Loyola University Chicago Stritch School of Medicine, Maywood, IL.
  • Flinn IW; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN.
  • Farooq U; University of Iowa, Iowa City, IA.
  • Goy AH; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.
  • McSweeney PA; Colorado Blood Cancer Institute, Denver, CO.
  • Munoz J; Department of Hematology, Mayo Clinic, Phoenix, AZ.
  • Siddiqi T; Division of Lymphoma, City of Hope National Medical Center, Duarte, CA.
  • Chavez JC; Moffitt Cancer Center, Tampa, FL.
  • Herrera AF; Division of Lymphoma, City of Hope National Medical Center, Duarte, CA.
  • Bartlett NL; Washington University School of Medicine and Siteman Cancer Center, St Louis, MO.
  • Bot AA; Kite, a Gilead Company, Santa Monica, CA.
  • Shen RR; Kite, a Gilead Company, Santa Monica, CA.
  • Dong J; Kite, a Gilead Company, Santa Monica, CA.
  • Singh K; Kite, a Gilead Company, Santa Monica, CA.
  • Miao H; Kite, a Gilead Company, Santa Monica, CA.
  • Kim JJ; Kite, a Gilead Company, Santa Monica, CA.
  • Zheng Y; Kite, a Gilead Company, Santa Monica, CA.
  • Locke FL; Moffitt Cancer Center, Tampa, FL.
Blood ; 141(19): 2307-2315, 2023 05 11.
Article in En | MEDLINE | ID: mdl-36821768
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biological Products / Lymphoma, Large B-Cell, Diffuse / Receptors, Chimeric Antigen Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Blood Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biological Products / Lymphoma, Large B-Cell, Diffuse / Receptors, Chimeric Antigen Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Blood Year: 2023 Type: Article